Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma Preliminary results of a phase I/II clinical trial

Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma : Preliminary results of a phase I/II clinical trial

Copyright © 2022. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 238(2022) vom: 01. Mai, Seite 108992
1. Verfasser: Cheng, Xiaobo (VerfasserIn)
Weitere Verfasser: Wang, Jing, Qiu, Chenli, Jin, Yanling, Xia, Bili, Qin, Ran, Hu, Huiliang, Yan, Jia, Zhang, Xiaoyan, Xu, Jianqing
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't Immunotherapy Lung adenocarcinoma Natural killer T-cells Antineoplastic Agents, Immunological Immunologic Factors Programmed Cell Death 1 Receptor
Beschreibung
Zusammenfassung:Copyright © 2022. Published by Elsevier Inc.
We performed a single-arm exploratory clinical trial that is ongoing and registered at ClinicalTrials.gov (NCT03093688). Patients were infused with autologous iNKT cells, PD-1 + CD8+ T cells, and dendritic cells every 3-5 weeks, which was considered 1 cycle. The primary endpoints were safety and objective tumor response. The preliminary results from the first three patients are reported here. The first patient received 16 cycles. Computed tomography (CT) examination revealed a stable disease (SD) response after 4 cycles and progressive disease (PD) response after 11 cycles. For the second patient that received 10 cycles, CT examination revealed an SD response after 4 cycles and a PD response after 9 cycles. For the third patient who was treated with 6 cycles, CT examination revealed an SD response after 4 cycles. The patients suffered from only grade 1-2 adverse events. iNKT cell and PD-1 + CD8+ T cell-based immunotherapy showed a manageable tolerability profile
Beschreibung:Date Completed 17.05.2022
Date Revised 20.05.2022
published: Print-Electronic
ClinicalTrials.gov: NCT03093688
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2022.108992